Hepatic veno-occlusive disease: A chemotherapy-related toxicity in children with malignancies

Pediatric Drugs

Volumn 12, Issue 5, 2010, Pages 277-284

  Cefalo, Maria Giuseppina ^a   Maurizi, Palma ^a   Arlotta, Annalisa ^a   Scalzone, Maria ^a   Attin, Giorgio ^a   Ruggiero, Antonio ^a   Riccardi, Riccardo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Antineoplastics, adverse reactions; Cancer; Children; Defibrotide, therapeutic use; Hepatic veno occlusive disease, prevention; Hepatic veno occlusive disease, treatment

Indexed keywords

ACICLOVIR; ACTIVATED PROTEIN C; ALKYLATING AGENT; ALTEPLASE; AMPHOTERICIN B; ANALGESIC AGENT; ANTHRACYCLINE; ANTITHROMBIN III; BUSULFAN; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DACTINOMYCIN; DEFIBROTIDE; DIURETIC AGENT; FIBRINOLYTIC AGENT; GEMTUZUMAB OZOGAMICIN; HEPARIN; LOMUSTINE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; NORETHISTERONE; PROSTAGLANDIN E1; TIOGUANINE; URSODEOXYCHOLIC ACID; VANCOMYCIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANALGESIA; ARTIFICIAL VENTILATION; ASCITES; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEVER; FLUID RETENTION; GOLD STANDARD; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERCOAGULABILITY; HYPOALBUMINEMIA; HYPOCHOLESTEROLEMIA; IMMUNOREGULATION; IRRADIATION; JAUNDICE; LIVER BIOPSY; LIVER METASTASIS; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MEDULLOBLASTOMA; MULTIPLE ORGAN FAILURE; NEPHROBLASTOMA; NEUROBLASTOMA; NUTRITION; PAIN; PARACENTESIS; PATHOGENESIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; RHABDOMYOSARCOMA; RISK FACTOR; SEX; SODIUM RESTRICTION; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VENOUS PRESSURE; WEIGHT GAIN; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 77956363085     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11531840-000000000-00000     Document Type: Review

References (94)

1. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000 May; 64 (5): 281-291
2. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42
3. Jacobs P, Miller JL, Uys CJ, et al. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukemia. S Afr Med J 1979; 55: 5-10
4. Woods WG, Dehner LP, Nesbit ME, et al. Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation. Am J Med 1980; 68: 285-290
5. Shulman HM, McDonald GB. Liver disease after marrow transplantation. In: Sale GB, Shulman HM, editors. The pathology of bone marrow transplantation. New York: Mason, 1984: 104
6. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe venoocclusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744
7. Green DM, Finklestein JZ, Norkoul P, et al. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine: a report of the National Wilms Tumor Study. Cancer 1988; 62: 270-273
8. Ortega JA, Donaldson SS, Maurer HM, et al. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Cancer 1997; 79 (12): 2435-2439
9. Bearman SI. The syndrome of veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020
10. Eber SW, Gungor T, Veldman A, et al. Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease. Ped Transplant 2007; 11: 49-57
11. Allen JR, Carstens LA, Katagiri GJ. Hepatic veins of monkeys with venoocclusive disease. Arch Pathol 1969; 87: 279-289
12. Shulman HM, McDonald GB, Matthews D, et al. An analysis of hepatic venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79: 1178-1191
13. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease: liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplantation 1992; 10 (3): 197-214
14. el Mouehli M, Kauffmann FC. Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology 1986; 6: 450-456
15. Sartori MT, Spiezia L, Cesaro S, et al. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population. Thromb Haemost 2005; 93 (4): 682-689
16. Smith LH, Dixon JD, Stringham JR, et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107 (1): 132-134
17. Pihusch V, Pihusch M, Penovici M, et al. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res 2005; 116 (3): 233-240
18. Faioni EM, Krachmalnicoff A, Bearman SI, et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venoocclusive disease of the liver. Blood 1993; 81 (12): 3458-3462
19. Kaleelrahman M, Eaton JD, Leeming D, et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic venoocclusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology 2003; 8 (2): 91-95
20. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development ofmajor transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17 (6): 1150-1156
21. Dickinson AM, Holler E. Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol 2008; 21 (2): 149-164
22. Petaja J, Pitkanen S, Vettenranta K, et al. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res 2000; 26: 881-886
23. Bayraktar UD, Seren S, Bayraktar Y. Hepatic venous outflow obstruction: three similar syndromes. World J Gastroenterol 2007; 13 (13): 1912-1927
24. Shulman HM, Fisher LB, Schoch HG, et al. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171-1180
25. Jevtić D, Vujić D, Zecević Z, et al. Coagulation disturbances in paediatric patients with hepatic veno-occlusive disease after stem cells transplantation. Srp Arh Celok Lek 2010; 138 Suppl. 1: 33-38
26. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and hemostasis. Blood Rev 2003; 17: 63-70
27. McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive disease after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122
28. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44 (6): 778-783
29. Khoury NJ, Kanj V, Abboud M, et al. Abdominal complications of chemotherapy in pediatric malignancies: imaging findings. Clin Imaging 2009; 33 (4): 253-260
30. Ghersin E, Brook OR, Gaitini D, et al. Color Doppler demonstration of segmental portal flow reversal: an early sign of hepatic veno-occlusive disease in an infant. J Ultrasound Med 2003; 22: 1103-1106
31. Senzolo M, Burra P, Cholongitas E, et al. The transjugular route: the key hole to the liver world. Dig Liver Dis 2007 39: 105-116
32. Lassau N, Auperin A, Leclere J, et al. Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease. Transplantation 2002; 74: 60-66
33. Cholongitas E, Quaglia A, Samonakis D, et al. Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut 2006; 55: 1789-1794
34. Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 9: 1729-1736
35. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267
36. Richardson PG, Murakami C, Jin Z. Multi-institutional use of defibrotide in 88 patients after stemcell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a highrisk population and factors predictive of outcome. Blood 2002; 100: 4337-43
37. Nevill TJ, Barnett MJ, Klingemann HG, et al. Regimen-related toxicity of busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232
38. Ganem G, Saint-Marc Girardin MF, KuentzM, et al. Venoocclusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Rad Oncol Biol Phys 1988; 14: 879-884
39. Hagglund H, Remberger M, Klaesson S, et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92: 4568-4572
40. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92 (10): 3599-3604
41. Matute-Bello G, McDonald GB, Hinds MS, et al. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21: 1125-1130
42. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11 (2): 304-313
43. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplantation recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730
44. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic venoocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135-141
45. Essel JH, Thompson JM, Harman GS. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784
46. Green DM. Wilms tumour. Eur J Cancer 1997; 33: 409-18
47. Farber S. Soft tissue sarcomas. Eur J Cancer 1997; 33: 2230-2234
48. Sulis ML, Bessmertny O, Granowetter L, et al. Veno-occlusive disease in pediatric patients receiving actinomycinDand vincristine only for the treatment of rhabdomyosarcoma. J Pediatr Hematol Oncol 2004; 26 (12): 843-846
49. Davidson A, Pritchard J. Actinomycin D, hepatic toxicity andWilms tumour: a mystery explained? Eur J Cancer 1998; 34 (8): 1145-1148
50. Bisogno G, de Kraker J, Weirich A, et al. Veno-occlusive disease of the liver in children treated for Wilms tumour. Med Ped Oncol 1997; 29: 245-251
51. Green DM, Finkelstein JZ, Norkool P, et al. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. Cancer 1988; 62: 270-273
52. Pochedly C. Hazard of chemotherapy in congenital Wilms tumour. J Peds 1971; 79: 708-709
53. Tornesello A, Piciacchia D,Mastrangelo S, et al. Veno-occlusive disease of the liver in right-sided Wilms tumours. Eur J Cancer 1998; 34 (8): 1220-1223
54. Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002; 11 (2): 215-229
55. Lennard L, Richards S, Cartwright CS, et al. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 2006; 80: 375-383
56. ElliM, PinarliFG,Dagdemir A, et al.Veno-occlusive disease of the liver in a child after chemotherapy for brain tumor. Pediatr Blood Cancer 2006; 46 (4): 521-523
57. Czauderna P, Katski K, Kowalczyk J. Venoocclusive liver disease (VOD) as a complication of Wilms tumour management in the series of consecutive 206 patients. Eur J Pediatr Surg 2000; 10 (5): 300-303
58. McDonald GB, Sharma P, Matthews DE, et al. The clinical course of 53 patients with veno-occlusive disease of the liver after bone marrow transplantation. Transplantation 1985; 39 (6): 603-608
59. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-38
60. Khoury H, Adkins D, Trinkaus K, et al. Treatment of hepatic veno-occlusive disease with high-dose corticosteroids: an update on 28 stem cell transplant recipients. Blood 1998; 92: 1132a
61. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica 2006; 91 (6): 795-800
62. Marsa-Vila L, Gorin NC, La Porte JP, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47 (5): 346-352
63. Forrest DL, Thompson K, Dorcas VG, et al. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003; 31 (12): 1143-1149
64. Park SH, Lee MH, Lee H, et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29 (2): 137-143
65. Strasser SI, McDonald SJ, Schoch HG. Severe hepatocellular injury after hematopoietic cell transplant: incidence and etiology in 2136 consecutive patients. Hepatology 2000; 32: 299A
66. Hasegawa S, Horibe K, Kawabe T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant 1998; 22 (12): 1191-1197
67. Matsumoto Y, Horiike S, Sakagami J, et al. Early ultrasonographic diagnosis and clinical follow-up of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in a patient with acute lymphoblastic leukemia. Intern Med 2009; 48 (10): 831-835
68. Ludwig R, Weirich A, Abel U, et al. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999; 33 (5): 462-469
69. Brice K, Valerie B, Claire G, et al. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bonemarrow transplantation in paediatrics. Pharmacoepidemiol Drug Saf 2008; 17 (2): 135-143
70. Bleyzac N. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam Clin Pharmacol 2008; 22 (6): 605-608
71. Bartelink IH, Bredius RG, Belitser SV, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stemcell transplantation.BiolBloodMarrowTransplant 2009; 15 (2): 231-241
72. Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347-354
73. Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from venoocclusive disease. Bone Marrow Transplant 2007; 40: 79-82
74. Corbacioglu S, Honig M, Lahr G, et al. Stem cell transplantation in childrenwith infantile osteopetrosis is associated with a high incidence ofVOD,which could be prevented with defibrotide. Bone Marrow Transplant 2006; 38: 547-553
75. Qureshi A, Marshall L, Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008; 50 (4): 831-832
76. Wadleigh M, Ho V, Momtaz P, et al. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 2003; 10: 451-462
77. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED, editors. Hematopoietic cell transplantation. 2nd ed. Oxford: Blackwell Publishing, 1998
78. Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 1101-1104
79. Yoshimi A, Kato K, Maeda N, et al. Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA). Rinsho Ketsueki 2000; 41 (2): 103-108
80. Bearman SI, Lee JL, Baron AE, et al. Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-1506
81. Mertens R, Brost H, Granzen B, et al. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr 1999; Suppl. 3: 154-158
82. Peres E, Kintzel P, Dansey R, et al. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease. Blood Coagul Fibrinolysis 2008; 19 (3): 203-207
83. Ibrahim A, Pico JL, Maraninchi D, et al. Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. Bone Marrow Transplant 1991; 7 Suppl. 2: 53
84. Dong M, Lin Q, Wu XY. Efficiency of prevention and treatment of venoocclusive disease of the liver after allogeneic stem cell transplantation. Ai Zheng 2008; 27 (6): 646-649
85. Song JS, Seo JJ, Moon HN, et al. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci 2006; 21 (5): 897-903
86. Schriber J, Milk B, Shaw D, et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant 1999; 24 (12): 1311-1314
87. Chen IL, Yang SN, Hsiao CC, et al. Treatment with high-dose methylprednisolone for hepatic veno-occlusive disease in a child with rhabdomyosarcoma. Pediatr Neonatol 2008; 49 (4): 141-144
88. Akyüz C, CaClar K, Emir S, et al. High-dose methylprednisolone treatment of hepatic veno-occlusive disease in a child with Wilms tumor. Pediatr Hematol Oncol 2003; 20 (4): 345-349
89. Yakushijin K, Matsui T, Okamura A, et al. Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Kobe J Med Sci 2005; 51 (3-4): 55-65
90. Falanga A, Vignoli A, Marchetti M, et al. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17: 1636-1642
91. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. 2008; 41: 229-237
92. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-1129
93. Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396-1404
94. Ammann RA. Defibrotide for hepatic VOD in children: exact statistics can help! Bone Marrow Transplant 2004; 34 (3): 277-278